VIDEO: Expert discusses ‘practice-changing’ findings from RxPonder study
The oncotype DX assay better predicted the benefits of chemotherapy among patients with HR-positive breast cancer and one to three positive lymph nodes, according to findings from the RxPonder study presented at the San Antonio Breast Cancer Symposium.
“I do think that was probably one of the most practice-changing studies presented at San Antonio,” Sara M. Tolaney, MD, MPH, an assistant professor of medicine at Harvard Medical School and a breast medical oncologist with Dana-Farber Cancer Institute, told Healio in a video interview.
Tolaney also discussed findings from the monarchE and PENELOPE-B studies and advised clinicians to take caution when analyzing the data.
Collapse
Kalinsky K. Abstract GS3-00. Presented at: San Antonio Breast Cancer Symposium (Virtual); Dec. 8-11, 2020.
Loibl S. Abstract GS1-02. Presented at: San Antonio Breast Cancer Symposium (Virtual); Dec. 8-11, 2020.
O'Shaughnessy JA. Abstract GS1-01. Presented at: San Antonio Breast Cancer Symposium (Virtual); Dec. 8-11, 2020.
Read more about